Discover the Myogenes story
We are honoured to support and present Myogenes, a company spearheaded by the visionary Clare Brenner, dedicated to revolutionising care for those with treatment-resistant schizophrenia.
In this revealing video, Clare shares her profound personal experiences that led to the creation of Myogenes. Her story sheds light on the urgent need for better treatment options and her mission to deliver precise, life-altering solutions to those in dire need.
Eliminating guesswork
Mental health issues affect around 1-in-4 of us, yet conventional treatments frequently fail the most vulnerable.
Myogenes challenges these norms through state-of-the-art pharmacogenetic technology. The goal is clear: to ensure patients receive the most effective treatment tailored specifically for them, eliminating the guesswork often associated with traditional methods.
Addressing treatment-resistent schizophrenia
Despite advances in medical science, the journey for those diagnosed with schizophrenia remains fraught with uncertainty and ineffectiveness. Particularly for those with treatment-resistant forms of the condition (around 1-in-3), the standard approach to care often leads to treatment cycles often fraught with trial and error that not only fail to alleviate symptoms but can also cause profound suffering and despair.
These individuals are often subjected to increased risks, including prolonged hospital stays, a higher likelihood of social withdrawal, and a significantly increased risk of suicide.
Myogenes: the path to effective treatment
Myogenes believes in a future where mental health treatment is as precise and individualised as the patients it serves.
Its breakthrough pharmacogenetic test embodies this vision by determining the most effective medication and dosage for individuals suffering from treatment-resistant schizophrenia.
A non-invasive saliva test is all it takes to start. This easy process can be completed at home or in a clinical setting, ensuring accessibility for all.
The test analyzes the patient's DNA to identify genetic markers that predict how they will metabolize clozapine alongside other critical information.
This helps prevent the trial-and-error approach that defines traditional psychiatric treatment.
Better patient outcomes and reduced healthcare costs
Armed with the critical information the Myogenes clozapine test provides, clinicians can prescribe the only approved and effective medication for treatment-resistant schizophrenia with a much greater level of confidence, helping to address the widespread underuse of this vital medication.
By eliminating ineffective treatments and reducing side effects, the Myogenes clozapine test can significantly lower healthcare expenditures associated with treatment-resistant schizophrenia.
Access our research on Myogenes
We have produced a detailed research note on Myogenes and its clozapine test.
The company is currently raising a £1mn SAFE/ASA round in order to enable the business to build an appropriately scaled medical and commercial infrastructure to launch the clozapine pharmacogenetic test in the initial target markets.
To find out more, book a call with us or access the research report.
